Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xiaoke Pill plus dapagliflozin for type 2 diabetes mellitus with metabolic syndrome
ChiCTR2400090109Phase 4Completed
- Sponsor
- Shaowu Municipal Hospital
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Xiaoke Pill and dapagliflozin in type 2 diabetes mellitus (T2DM) and cardiometabolic risk (CMR) (2 arms), sponsored by Shaowu Municipal Hospital. Primary endpoints: fasting plasma glucose, 2-hour postprandial plasma glucose and 13 more. Started Sep 2024; status: completed.
02
Drugs
Xiaoke Pilldapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)cardiometabolic risk (CMR)
Beyond the preview
Go deeper on ChiCTR2400090109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090109.